COVID-19: Accurately & Precisely Evaluate Endpoint Data Date Published: May 05, 2020 Whitepaper Signant’s Anthony Everhart discusses that when it comes to maintaining accuracy and precision in clinical trials during the pandemic, it’s important to consider endpoint data and methods for validity. In general, there are two primary approaches: simplification and modification. The white paper details the three key considerations with simplification: Determine endpoint data risks Modify the protocol to collect less data Consult with the right committees The paper argues that rapid modernization and decentralization of clinical trials should become more of the norm even beyond COVID-19. Download Now Share: LinkedInTweet Recommended Resources 3 Themes and Takeaways From FDA’s Draft Guidance on DCTs Download Now Whitepaper Computerized Adaptive Tests Using PROMIS CAT Download Now Whitepaper The EMA Recommendation Paper on Decentralized Elements in Clinical Trials: An Overview Read Our White Paper Whitepaper